Clinical trialNCT06827613RecruitingPhase 1/PHASE2Interventional

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

SponsorMarengo Therapeutics, Inc.Enrollment50HR+, HER2-, Advanced Breast CancerTriple Negative Locally Advanced Non-resectable Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Bc Cancer
Vancouver, British Columbia, Canada
Nathalie LeVasseur, MD
Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Philippe Bedard, MD, FRCPC
Recruiting

United States

Ucla Health
Los Angeles, California, United States
Aditya Bardia, MD, MPHKelly E McCann, MD, PhD
Recruiting
Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
Anastasia Martynova, MD
Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
Steven Isakoff, MD, PhD, MMSC
Recruiting
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Margaret Gatti-Mays, MD, MPH, FACP
Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Erika Hamilton, MD
Recruiting
Ut Health San Antonio Md Anderson Cancer Center
San Antonio, Texas, United States
Virginia Kaklamani, MD DSc
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

STAR0602 →Sacituzumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Mar 2025
Primary completion: 31 Jan 2027
Completion: 31 Jan 2028
Last update posted: 24 Sept 2025
Registered enrollment: 50
Registry id: NCT06827613

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.